Featured Publications
Racial and Ethnic Disparities in Access to and Outcomes of Infertility Treatment and Assisted Reproductive Technology in the United States
Beroukhim G, Seifer D. Racial and Ethnic Disparities in Access to and Outcomes of Infertility Treatment and Assisted Reproductive Technology in the United States. Endocrinology And Metabolism Clinics Of North America 2023, 52: 659-675. PMID: 37865480, DOI: 10.1016/j.ecl.2023.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAmerican Indian or Alaska NativeAsianBlack or African AmericanEthnicityFemaleHealth Services AccessibilityHealthcare DisparitiesHispanic or LatinoHumansInfertilityInfertility, FemalePregnancyPregnancy OutcomeReproductive Techniques, AssistedSocial Determinants of HealthUnited StatesWhiteConceptsEthnic disparitiesInfertility treatmentIntrauterine insemination pregnancy ratesHigh infertility rateAmerican Indian womenAssisted Reproductive TechnologyClinical pregnancyObstetrical complicationsFertility carePregnancy lossFavorable outcomePregnancy rateInfertility rateLive birthsHigher oddsART outcomesHispanic womenWhite womenRobust studiesWomenIndian womenReproductive technologiesBlack womenOutcomesCare
2023
AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles
Arkfeld C, Han E, Tal R, Seifer D. AMH predicts miscarriage in non-PCOS but not in PCOS related infertility ART cycles. Reproductive Biology And Endocrinology 2023, 21: 35. PMID: 37020210, PMCID: PMC10074664, DOI: 10.1186/s12958-023-01087-5.Peer-Reviewed Original ResearchConceptsBody mass indexMiscarriage rateMean AMHART cyclesNumber of embryosElevated AMHAMH valuesOdds ratioNon-PCOS patientsOverall miscarriage rateConfidence intervalsAutologous embryo transferSART CORS databaseMultivariate regression analysisHeterotopic pregnancyClinical pregnancyAMH levelsIVF cyclesPCOS patientsPCOS populationIndependent predictorsMass indexPatient populationOocyte bankingAutologous transfer
2020
Do state insurance mandates alter ICSI utilization?
Zagadailov P, Seifer DB, Shan H, Zarek SM, Hsu AL. Do state insurance mandates alter ICSI utilization? Reproductive Biology And Endocrinology 2020, 18: 33. PMID: 32334609, PMCID: PMC7183130, DOI: 10.1186/s12958-020-00589-w.Peer-Reviewed Original ResearchConceptsIntracytoplasmic sperm injectionElective single embryo transferClinical pregnancyICSI usePreimplantation genetic testingESET rateState insurance mandatesTwin rateInsurance mandatesRetrospective cohort studyLive birth rateLower clinical pregnancyMale factor infertilitySingle embryo transferBirth rateTwin birth rateT-testICSI rateLower LBRStrength of associationCohort studyFactor infertilityART cyclesResultsFrom 2000ART coverage
2015
Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013
Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013. Fertility And Sterility 2015, 105: 385-393.e3. PMID: 26515380, DOI: 10.1016/j.fertnstert.2015.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersCryopreservationDatabases, FactualEmbryo TransferFemaleFertilityFertilization in VitroHumansInfertilityLinear ModelsLive BirthLogistic ModelsMiddle AgedMultivariate AnalysisOocyte RetrievalPatient SelectionPregnancyPregnancy RatePregnancy, MultipleReproductive Techniques, AssistedRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeYoung AdultConceptsLive birth rateAntimüllerian hormoneCancellation rateAMH levelsAssisted Reproductive Technology Clinic Outcome Reporting System databaseAssisted reproduction technology (ART) outcomesEmbryo cryopreservation ratesSerum antimüllerian hormoneTotal cancellation rateMultiple birth ratesReporting System databaseCycle startAutologous cyclesClinical pregnancyCycle cancellationPrognostic factorsAMH valuesFresh cyclesCycle outcomePrognostic indicatorAMH concentrationsRetrospective analysisMAIN OUTCOMEEmbryo transferMultivariate analysis
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Disparities Between Black and White Women in Assisted Reproductive Technology
Tal R, Seifer D. Disparities Between Black and White Women in Assisted Reproductive Technology. 2013, 73-83. DOI: 10.1007/978-1-4614-7548-4_5.ChaptersBlack race/ethnicityLower clinical pregnancyReproductive technologiesUS health care systemHealth care systemAssisted Reproductive TechnologyRace/ethnicityClinical pregnancyPoor outcomeLive birthrateSevere diseaseART outcomesWhite womenCare systemSocioeconomic statusGenetic factorsSuch disparitiesOutcomesPregnancyConfoundersDisparitiesDisease
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
1998
Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential
Friedman C, Seifer D, Kennard E, Arbogast L, Alak B, Danforth D. Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertility And Sterility 1998, 70: 836-839. PMID: 9806563, DOI: 10.1016/s0015-0282(98)00301-x.Peer-Reviewed Original ResearchConceptsFF VEGF concentrationsAmpules of gonadotropinsVEGF concentrationsClinical pregnancyChart reviewFollicular fluid vascular endothelial growth factorFollicular fluid vascular endothelial growth factor concentrationsDay 3 FSH levelsFollicular fluid VEGF concentrationsVascular endothelial growth factor concentrationsClinical pregnancy rateEstradiol serum concentrationsPeak estradiol levelsRetrospective chart reviewUniversity teaching centerVascular endothelial growth factorNumber of oocytesYears of ageEndothelial growth factorGrowth factor concentrationsFF VEGFSingle IVFFSH levelsPatient ageEstradiol levels
1997
Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome
Seifer D, Lambert-Messerlian G, Hogan J, Gárdiner A, Blazar A, Berk C. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility And Sterility 1997, 67: 110-114. PMID: 8986693, DOI: 10.1016/s0015-0282(97)81865-1.Peer-Reviewed Original ResearchConceptsClinical pregnancy rateNumber of oocytesSerum inhibin B concentrationPg/mLInhibin B concentrationsSerum inhibinPregnancy ratePg/Clinical pregnancyOvulation inductionSerum E2Poor responseCancellation rateDay 3 serum FSHAssisted reproductive technology cyclesGnRH agonist suppressionInhibin B valuesReproductive technology cyclesDay of hCGSpontaneous abortion rateAcademic clinical practiceReproductive technologiesSerum FSHOdds ratioE2 response
1994
Reproductive potential after treatment for persistent ectopic pregnancy **Presented in part at the conjoint meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993.
Seifer D, Silva P, Grainger D, Barber S, Grant W, Gutmann J. Reproductive potential after treatment for persistent ectopic pregnancy **Presented in part at the conjoint meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993. Fertility And Sterility 1994, 62: 194-196. PMID: 8005291, DOI: 10.1016/s0015-0282(16)56841-1.Peer-Reviewed Original ResearchConceptsContralateral fallopian tubeClinical pregnancy rateFallopian tubePregnancy rateCumulative clinical pregnancy rateIntrauterine pregnancy ratePersistent ectopic pregnancyAmerican Fertility SocietyClinical pregnancyEctopic pregnancyTreatment failureCanadian FertilityAndrology SocietySuccessful treatmentPrimary treatmentFertility SocietyRelative riskReproductive outcomesConjoint MeetingObvious pathologySignificant associationSuccess rateTreatmentPregnancySalpingectomy